Adropin: A Game Changer in Diabetes? Exploring Its Role in Metabolism, Biomarkers, and Therapy

Abstract

Adropin, a regulatory peptide hormone whose gene is encoded by the energy homeostasis-associated gene (ENHO), is an important carbohydrate and lipid metabolism modulator. Its widespread expression in different tissues such as the brain, liver, and endothelial cells reflects its systemic action on metabolic pathways. Interestingly, decreased levels of circulating adropin have been found in obese and T2DM subjects, and therefore, it was hypothesized to be involved in metabolic dysregulation. Here, the complexity of adropin in diabetes is reviewed based on its possibility as a biomarker for various forms of diabetes and as an indicator of bad diabetic outcomes. In addition, we discuss recent experimental evidence showing the protective role of adropin treatment in preventing diabetes-associated complications. Elucidation of the mechanisms through which adropin has its actions on glucose metabolism and insulin sensitivity can be a starting point for the development of new therapeutic approaches to treating diabetes and metabolic syndrome.

Introduction

Diabetes mellitus, an uncontrolled chronic metabolic disorder defined by disrupted glucose homeostasis, is an increasing global health problem. Diabetes pathophysiology involves an intricate interplay between hormonal, environmental, and genetic factors. Of newly emerging hormonal regulators, adropin has recently received much interest for its potential involvement in energy balance, lipid metabolism, and insulin sensitivity. Though first recognized as a central regulator of energy homeostasis, the latest research has implicated adropin in larger roles in metabolic diseases, such as diabetes. The present review is designed to clarify the function of adropin in diabetes pathogenesis, consider its promise as a biomarker, and explore its therapeutic significance in the fight against metabolic dysfunction that characterizes diabetes.

The Biology of Adropin

Adropin is a peptide hormone encoded by the ENHO gene and is primarily expressed in the liver, brain, pancreas, and vascular endothelium. It is regulated by dietary intake and metabolic status, with higher expression observed under normal physiological conditions and downregulation seen in metabolic disorders such as obesity and diabetes. Functionally, adropin is involved in:

1. Glucose Metabolism: Adropin enhances insulin sensitivity and promotes glucose uptake by skeletal muscles, reducing hyperglycemia in diabetic states.

2. Lipid Metabolism: It plays a vital role in maintaining lipid homeostasis by regulating fatty acid oxidation and suppressing lipogenesis.

3. Energy Homeostasis: Adropin influences feeding behavior and energy expenditure, contributing to body weight regulation.

4. Cardiovascular Function: It exerts protective effects on endothelial cells, reducing oxidative stress and inflammation, common contributors to diabetic complications.

Adropin as a Biomarker for Diabetes

Recent clinical and experimental studies indicate that adropin levels are significantly altered in patients with diabetes, making it a promising biomarker for disease prediction and progression. Observational studies have reported:

• Lower circulating adropin levels in individuals with insulin resistance and T2DM.

• An inverse correlation between adropin levels and glycemic indices such as fasting glucose, HbA1c, and insulin resistance markers.

• Associations between decreased adropin levels and increased risk of diabetic complications, including nephropathy, neuropathy, and cardiovascular diseases.

Given these findings, adropin measurement in clinical settings may provide valuable insights into diabetes risk assessment and disease monitoring.

The Therapeutic Potential of Adropin in Diabetes

Preclinical studies have demonstrated that adropin supplementation exerts protective effects against diabetes-related metabolic disturbances. Key findings from animal models include:

• Improvement in Insulin Sensitivity: Adropin administration enhances glucose tolerance and increases insulin receptor signaling in skeletal muscles.

• Reduction in Lipid Accumulation: Treatment with adropin decreases hepatic steatosis and promotes fatty acid oxidation, mitigating the risk of non-alcoholic fatty liver disease (NAFLD) in diabetes.

• Anti-Inflammatory Effects: Adropin reduces pro-inflammatory cytokines and oxidative stress, which are implicated in diabetes pathogenesis and complications.

• Neuroprotective Properties: Emerging evidence suggests that adropin may have protective effects against cognitive dysfunction and neurodegenerative changes observed in diabetes.

Mechanistic Insights: How Adropin Modulates Metabolic Pathways

The molecular mechanisms underlying adropin’s metabolic effects involve multiple pathways, including:

• AMPK Activation: Adropin stimulates AMP-activated protein kinase (AMPK), a key regulator of glucose and lipid metabolism, enhancing cellular energy homeostasis.

• PI3K/Akt Pathway: It enhances insulin receptor signaling through the phosphoinositide 3-kinase (PI3K)/Akt pathway, improving glucose uptake and utilization.

• Regulation of Mitochondrial Function: Adropin improves mitochondrial efficiency and biogenesis, leading to enhanced energy production and reduced oxidative stress.

Clinical Implications and Future Directions

Despite promising preclinical evidence, clinical translation of adropin-based therapies remains in its early stages. Future research should focus on:

• Developing Synthetic Adropin Analogs: Designing stable and bioavailable adropin analogs for therapeutic use in diabetes management.

• Large-Scale Clinical Trials: Conducting randomized controlled trials to evaluate the efficacy and safety of adropin supplementation in diabetic patients.

• Exploring Combination Therapies: Investigating the potential of adropin in combination with existing antidiabetic drugs to enhance therapeutic outcomes.

Conclusion

Adropin has also emerged as a novel biomarker and therapeutic target in the management of diabetes. Its function in the regulation of glucose metabolism, lipid homeostasis, and insulin sensitivity makes it a potential biomarker for disease prediction and therapy. Although preclinical data strongly support its beneficial role, additional research is needed to translate the results into clinical use. Leverage of atropin's metabolic regulatory function could unlock new pathways for novel therapeutic approaches to fight diabetes and its complications.